by B2i | Oct 4, 2022 | Press Releases
JUPITER, Fla., Oct. 04, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Sep 13, 2022 | Press Releases
JUPITER, Fla., Sept. 13, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Sep 8, 2022 | Press Releases
JUPITER, Fla., Sept. 08, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Aug 10, 2022 | Press Releases
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from proprietary C1-cell protein production platform and demonstrate...
by B2i | Jul 27, 2022 | Press Releases
JUPITER, Fla., July 27, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...